Huntington disease: Natural history, biomarkers and prospects for therapeutics

Nature Reviews Neurology

Volumn 10, Issue 4, 2014, Pages 204-216

  Ross, Christopher A ^a   Aylward, Elizabeth H ^b   Wild, Edward J ^c   Langbehn, Douglas R ^d   Long, Jeffrey D ^d   Warner, John H ^e   Scahill, Rachael I ^c   Leavitt, Blair R ^f   Stout, Julie C ^g   Paulsen, Jane S ^d   Reilmann, Ralf ^h   Unschuld, Paul G ⁱ   Wexler, Alice ^j   Margolis, Russell L ^a   Tabrizi, Sarah J ^c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Seattle Children's Research Institute   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF IOWA   (United States)

^e CHDI MANAGEMENT CHDI FOUNDATION   (United States)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g MONASH UNIVERSITY   (Australia)

^h George Huntington Institute   (Germany)

ⁱ UNIVERSITY OF ZURICH   (Switzerland)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; BIOLOGICAL MARKER; CREATINE; HUNTINGTIN; PHOSPHOPROTEIN DARPP 32; UBIDECARENONE;

CAG REPEAT; CHOREA; COGNITIVE DEFECT; DIFFUSION TENSOR IMAGING; DISEASE COURSE; DRUG RESPONSE; EMOTIONAL DISORDER; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE; GENE MUTATION; HTT GENE; HUMAN; HUNTINGTON CHOREA; MOTOR DYSFUNCTION; NERVE CELL NECROSIS; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; UNIFIED HUNTINGTON DISEASE RATING SCALE;

BIOLOGICAL MARKERS; BRAIN; HUMANS; HUNTINGTON DISEASE; MAGNETIC RESONANCE IMAGING; NEUROIMAGING;

EID: 84898017417     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2014.24     Document Type: Review

References (146)

1. Squitieri, F & Jankovic, J. Huntington's disease: How intermediate are intermediate repeat lengths?. Mov. Disord. 27, 1714-1717 (2012
2. Seong, I. S. et al. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum. Mol. Genet. 14, 2871-2880 (2005
3. Huntington, G. On chorea. Med. Surg. Reporter 26, 320-321 (1872
4. Folstein, S. E. The psychopathology of Huntington's disease. J. Nerv. Ment. Dis. 177, 645 (1989
5. [No authors listed] Unified Huntington's disease rating scale: Reliability and consistency. Huntington Study Group. Mov. Disord. 11, 136-142 (1996
6. Hogarth, P. et al. Interrater agreement in the assessment of motor manifestations of Huntington's disease. Mov. Disord. 20, 293-297 (2005
7. Weir, D. W., Sturrock, A. & Leavitt, B. R. Development of biomarkers for Huntington's disease. Lancet Neurol. 10, 573-590 (2011
8. Shoulson, I. & Fahn, S. Huntington Disease: Clinical care and evaluation. Neurology 29, 1-3 (1979
9. Shoulson, I. Huntington Disease: Functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology 31, 1333-1335 (1981
10. [No authors listed] A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 72, 971-983 (1993
11. Wexler, N. S. et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc. Natl Acad. Sci. USA 101, 3498-3503 (2004
12. Paulsen, J. S. et al. Detection of Huntington's disease decades before diagnosis: The Predict-HD study. J. Neurol. Neurosurg. Psychiatry 79, 874-880 (2008
13. Tabrizi, S J. et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: Cross-sectional analysis of baseline data. Lancet Neurol. 8, 791-801 (2009
14. Tabrizi, S. J. et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: The 12-month longitudinal analysis. Lancet Neurol. 10, 31-42 (2011
15. Tabrizi, S. J. et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: Analysis of 24 month observational data. Lancet Neurol. 11, 42-53 (2012
16. Tabrizi, S. J. et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: Analysis of 36-month observational data. Lancet Neurol. 12, 637-649 (2013
17. Orth, M. et al. Observing Huntington's disease: The European Huntington's Disease Network's REGISTRY. J. Neurol. Neurosurg. Psychiatry 82, 1409-1412 (2010
18. Rosenblatt, A. et al. Predictors of neuropathological severity in 100 patients with Huntington's disease. Ann. Neurol. 54, 488-493 (2003
19. Langbehn, D. R., Hayden, M. R. & Paulsen, J. S. CAG-repeat length and the age of onset in Huntington Disease (HD): A review and validation study of statistical approaches. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153B, 397-408 (2010
20. Rosenblatt, A. et al. Age, CAG repeat length, and clinical progression in Huntington's disease. Mov. Disord. 27, 272-276 (2012
21. Penney, J. B. Jr, Vonsattel, J. P., MacDonald, M. E., Gusella, J. F. & Myers, R. H. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann. Neurol. 41, 689-692 (1997
22. Zhang, Y. et al. Indexing disease progression at study entry with individuals at-risk for Huntington Disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 156B, 751-763 (2011
23. Huntington Study Group COHORT Investigators & Dorsey, E. Characterization of a large group of individuals with Huntington Disease and their relatives enrolled in the COHORT study. PLoS ONE 7, e29522 (2012
24. Dorsey, E. R. et al. Natural history of Huntington Disease. JAMA Neurol. 70, 1520-1530 (2013
25. Rosenblatt, A. et al. The association of CAG repeat length with clinical progression in Huntington Disease. Neurology 66, 1016-1020 (2006
26. Folstein, S. E., Jensen, B., Leigh, R. J. & Folstein, M. F. The measurement of abnormal movement: Methods developed for Huntington's disease. Neurobehav. Toxicol. Teratol. 5, 605-609 (1983
27. Bechtel, N. et al. Tapping linked to function and structure in premanifest and symptomatic Huntington Disease. Neurology 75, 2150-2160 (2010
28. Reilmann, R. et al. Q Motor-quantitative motor assessments: Potential novel endpoints for clinical trials in pre-manifest and symptomatic Huntington's disease-36 months longitudinal results from the multicenter TRACK-HD study. Basal Ganglia 3, 67-68 (2013
29. Reilmann, R. et al. Objective assessment of progression in Huntington's disease: A 3 year follow-up study. Neurology 57, 920-924 (2001
30. Reilmann, R. et al. Grasping premanifest Huntington's disease-shaping new endpoints for new trials. Mov. Disord. 25, 2858-2862 (2010
31. Reilmann, R., Bohlen, S., Kirsten, F., Ringelstein, E. B. & Lange, H. W. Assessment of involuntary choreatic movements in Huntington's disease-Toward objective and quantitative measures. Mov. Disord. 26, 2267-2273 (2011
32. Stout, J. C. et al. Neurocognitive signs in prodromal Huntington Disease. Neuropsychology 25, 1-14 (2011
33. Stout, J. C. et al. Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease. J. Neurol. Neurosurg. Psychiatry 83, 687-694 (2012
34. Snowden, J. S., Craufurd, D., Thompson, J. & Neary, D. Psychomotor, executive, and memory function in preclinical Huntington's disease. J. Clin. Exp. Neuropsychol. 24, 133-145 (2002
35. Peavy, G. M. et al. Cognitive and functional decline in Huntington's disease: Dementia criteria revisited. Mov. Disord. 25, 1163-1169 (2010
36. Solomon, A. C. et al. Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia 45, 1767-1776 (2007
37. Duff, K. et al. 'Frontal behaviors before the diagnosis of Huntington's disease and their relationship to markers of disease progression: Evidence of early lack of awareness. J. Neuropsychiatry Clin. Neurosci. 22, 196-207 (2010
38. Thompson, J. C. et al. Longitudinal evaluation of neuropsychiatric symptoms in Huntington's disease. J. Neuropsychiatry Clin. Neurosci. 24, 53-60 (2012
39. Killoran, A. & Biglan, K. M. Therapeutics in Huntington's disease. Curr. Treat. Options Neurol. http://dx.doi.org/10.1007/s11940 012 0165 x.
40. Bjorkqvist, M., Wild, E. J. & Tabrizi, S. J. Harnessing immune alterations in neurodegenerative diseases. Neuron 64, 21-24 (2009
41. Wild, E., Bjorkqvist, M & Tabrizi, S. J. Immune markers for Huntington's disease?. Expert Rev. Neurother. 8, 1779-1781 (2008
42. Björkqvist, M. et al. et al. A novel pathogenic pathway of immune activation Detectable before clinical onset in Huntington's disease. J. Exp. Med. 205, 1869-1877 (2008
43. Battaglia, G. et al. Early defect of transforming growth factor β1 formation in Huntington's disease. J. Cell. Mol. Med. 15, 555-571 (2011
44. Kim, M. Beta conformation of polyglutamine track revealed by a crystal structure of Huntingtin N terminal region with insertion of three histidine residues. Prion 7, 221-228 (2013
45. Bence, N. F., Sampat, R. M. & Kopito, R. R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292, 1552-1555 (2001
46. Seredenina, T. & Luthi-Carter, R. What have we learned from gene expression profiles in Huntington's disease?. Neurobiol. Dis. 45, 83-98 (2012
47. Browne, S. E. et al. Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia. Ann. Neurol. 41, 646-653 (1997
48. Rosenblatt, A. et al. Familial influence on age of onset among siblings with Huntington Disease. Am. J. Med. Genet. 105, 399-403 (2001
49. Gusella, J. F. & MacDonald, M. E. Huntington's disease: Seeing the pathogenic process through a genetic lens. Trends Biochem. Sci. 31, 533-540 (2006
50. Lee, J. H. et al. TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease. Biochem. Biophys. Res. Commun. 424, 404-408 (2012
51. Ramos, E. M. et al. Population stratification may bias analysis of PGC 1a as a modifier of age at Huntington Disease motor onset. Hum. Genet. 131, 1833-1840 (2012
52. Gayán, J. et al. Genomewide linkage scan reveals novel loci modifying age of onset of Huntington's disease in the Venezuelan HD kindreds. Genet. Epidemiol. 32, 445-453 (2008
53. Roach, J. C. et al. Analysis of genetic inheritance in a family quartet by whole-genome sequencing. Science 328, 636-639 (2010
54. Ross, C. A. & Tabrizi, S. J. Huntington's disease: From molecular pathogenesis to clinical treatment. Lancet Neurol. 10, 83-98 (2011
55. Guo, Z. et al. Striatal neuronal loss correlates with clinical motor impairment in Huntington's disease. Mov. Disord. 27, 1379-1386 (2012
56. Cummings, D. M. et al. Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of Huntington's disease. Hum. Mol. Genet. 15, 2856-2868 (2006
57. Yamamoto, A., Lucas, J. J. & Hen, R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101, 57-66 (2000
58. Harper, S. Q. et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl Acad. Sci. USA 102, 5820-5825 (2005
59. Carroll, J. B. et al. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington Disease gene/allele-specific silencing of mutant huntingtin. Mol. Ther. 19, 2178-2185 (2011
60. Jucker, M. & Walker, L. C. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann. Neurol. 70, 532-540 (2011
61. Georgiou-Karistianis, N., Scahill, R., Tabrizi, S. J., Squitieri, F. & Aylward, E. Structural MRI in Huntington's disease and recommendations for its potential use in clinical trials. Neurosci. Biobehav. Rev. 37, 480-490 (2013
62. Aylward, E. H. et al. Longitudinal change in basal ganglia volume in patients with Huntington's disease. Neurology 48, 394-399 (1997
63. Aylward, E. H. et al. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease. Mov. Disord. 15, 552-560 (2000
64. Rosas, H. D. et al. Striatal volume loss in HD as measured by MRI and the influence of CAG repeat. Neurology 57, 1025-1028 (2001
65. Peinemann, A. et al. Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy: A neuropsychological and voxel-based morphometric study. J. Neurol. Sci. 239, 11-19 (2005
66. Ruocco, H. H., Lopes-Cendes, I., Li, L. M., Santos-Silva, M. & Cendes, F. Striatal and extrastriatal atrophy in Huntington's disease and its relationship with length of the CAG repeat. Braz. J. Med. Biol. Res. 39, 1129-1136 (2006
67. Henley, S. M. et al. Relationship between CAG repeat length and brain volume in premanifest and early Huntington's disease. J. Neurol. 256, 203-212 (2009
68. Vandenberghe, W., Demaerel, P., Dom, R. & Maes, F. Diffusion-weighted versus volumetric imaging of the striatum in early symptomatic Huntington Disease. J. Neurol. 256, 109-114 (2009
69. Ginestroni, A. et al. Magnetization transfer MR imaging demonstrates degeneration of the subcortical and cortical gray matter in Huntington Disease. AJNR Am. J. Neuroradiol. 31, 1807-1812 (2010
70. Sanchez-Castaneda, C. et al. Seeking Huntington Disease biomarkers by multimodal, cross-sectional basal ganglia imaging. Hum. Brain Mapp. 34, 1625-1635 (2012
71. Aylward, E. H. et al. Longitudinal change in regional brain volumes in prodromal Huntington Disease. J. Neurol. Neurosurg. Psychiatry 82, 405-410 (2011
72. Ruocco, H. H., Bonilha, L., Li, L. M., Lopes-Cendes, I. & Cendes, F. Longitudinal analysis of regional grey matter loss in Huntington Disease: Effects of the length of the expanded CAG repeat. J. Neurol. Neurosurg. Psychiatry 79, 130-135 (2008
73. Paulsen, J. S. et al. Striatal and white matter predictors of estimated diagnosis for Huntington Disease. Brain Res. Bull. 82, 201-207 (2010
74. Younes, L. et al. Regionally selective atrophy of subcortical structures in prodromal HD as revealed by statistical shape analysis. Hum. Brain Mapp. 35, 792-809 (2014
75. Rosas, H. D. et al. Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis. Neurology 60, 1615-1620 (2003
76. Rosas, H. D. et al. Cerebral cortex and the clinical expression of Huntington's disease: Complexity and heterogeneity. Brain 131, 1057-1068 (2008
77. Nopoulos, P. C. et al. Cerebral cortex structure in prodromal Huntington Disease. Neurobiol. Dis. 40, 544-554 (2010
78. Hobbs, N. Z. et al. The progression of regional atrophy in premanifest and early Huntington's disease: A longitudinal voxel-based morphometry study. J. Neurol. Neurosurg. Psychiatry 81, 756-763 (2010
79. Thieben, M. J. et al. The distribution of structural neuropathology in pre-clinical Huntington's disease. Brain 125, 1815-1828 (2002
80. Ciarmiello, A. et al. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J. Nucl. Med. 47, 215-222 (2006
81. Paulsen, J. S. et al. Brain structure in preclinical Huntington's disease. Biol. Psychiatry 59, 57-63 (2006
82. Beglinger, L. J. et al. White matter volume and cognitive dysfunction in early Huntington's disease. Cogn. Behav. Neurol. 18, 102-107 (2005
83. Crawford, H. E. et al. Corpus callosal atrophy in premanifest and early Huntington's disease. J. Huntingtons Dis. 2, 517-526 (2013
84. van Den Bogaard, S. J. et al. Shape analysis of subcortical nuclei in Huntington's disease, global versus local atrophy-results from the TRACK-HD study. J. Neurol. Sci. 307, 60-68 (2011
85. Reading, S. A. et al. Regional white matter change in pre-symptomatic Huntington's disease: A diffusion tensor imaging study. Psychiatry Res. 140, 55-62 (2005
86. Rosas, H. D. et al. Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures. Mov. Disord. 21, 1317-1325 (2006
87. Klöppel, S. et al. White matter connections reflect changes in voluntary-guided saccades in pre-symptomatic Huntington's disease. Brain 131, 196-204 (2008
88. Stoffers, D. et al. Contrasting gray and white matter changes in preclinical Huntington Disease: An MRI study. Neurology 74, 1208-1216 (2010
89. Douaud, G. et al. In vivo evidence for the selective subcortical degeneration in Huntington's disease. Neuroimage 46, 958-966 (2009
90. Della Nave, R. et al. Regional distribution and clinical correlates of white matter structural damage in Huntington Disease: A tract-based spatial statistics study. AJNR Am. J. Neuroradiol. 31, 1675-1681 (2010
91. Rosas, H. D. et al. Altered white matter microstructure in the corpus callosum in Huntington's disease: Implications for cortical 'disconnection. Neuroimage 49, 2995-3004 (2010
92. Sritharan, A. et al. A longitudinal diffusion tensor imaging study in symptomatic Huntington's disease. J. Neurol. Neurosurg. Psychiatry 81, 257-262 (2010
93. Bohanna, I. et al. Diffusion tensor imaging in Huntington's disease reveals distinct patterns of white matter degeneration associated with motor and cognitive deficits. Brain Imaging Behav. 5, 171-180 (2011
94. Delmaire, C. et al. The structural correlates of functional deficits in early huntington's disease. Hum. Brain Mapp. 34, 2141-2153 (2012
95. Paulsen, J. S. et al. fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington's disease. AJNR Am. J. Neuroradiol. 25, 1715-1721 (2004
96. Reading, S. A. et al. Functional brain changes in presymptomatic Huntington's disease. Ann. Neurol. 55, 879-883 (2004
97. Paulsen, J. S. Functional imaging in Huntington's disease. Exp. Neurol. 216, 272-277 (2009
98. Novak, M. J. et al. Altered brain mechanisms of emotion processing in pre-manifest Huntington's disease. Brain 135, 1165-1179 (2012
99. van Den Bogaard, S. J. et al. Magnetization transfer imaging in premanifest and manifest Huntington Disease. AJNR. Am. J. Neuroradiol. 33, 884-889 (2012
100. Klöppel, S. et al. Functional compensation of motor function in pre-symptomatic Huntington's disease. Brain 132, 1624-1632 (2009
101. Unschuld, P. G. et al. Impaired cortico-striatal functional connectivity in prodromal Huntington's disease. Neurosci. Lett. 514, 204-209 (2012
102. Wolf, R. C. et al. Default-mode network changes in preclinical Huntington's disease. Exp. Neurol. 237, 191-198 (2012
103. Mayberg, H. S. et al. Paralimbic frontal lobe hypometabolism in Depression associated with Huntington's disease. Neurology 42, 1791-1797 (1992
104. Kloppel, S. et al. Irritability in pre-clinical Huntington's disease. Neuropsychologia 48, 549-557 (2010
105. Unschuld, P. G. et al. Depressive symptoms in prodromal Huntington's disease correlate with Stroop-interference related functional connectivity in the ventromedial prefrontal cortex. Psychiatry Res. 203, 166-174 (2012
106. Unschuld, P. G. et al. Prefrontal executive function associated coupling relates to Huntington's disease stage. Cortex 49, 2661-2673 (2013
107. Wolf, R. C. et al. Altered frontostriatal coupling in pre-manifest Huntington's disease: Effects of increasing cognitive load. Eur. J. Neurol. 15, 1180-1190 (2008
108. Davie, C. A., Barker, G. J., Quinn, N., Tofts, P. S. & Miller, D. H. Proton MRS in Huntington's disease. Lancet 343, 1580 (1994
109. Jenkins, B. G. et al. 1H NMR spectroscopy studies of Huntington's disease: Correlations with CAG repeat numbers. Neurology 50, 1357-1365 (1998
110. Sturrock, A. et al. Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington Disease. Neurology 75, 1702-1710 (2010
111. Unschuld, P. G. et al. Brain metabolite alterations and cognitive dysfunction in early Huntington's disease. Mov. Disord. 27, 895-902 (2012
112. Rosas, H. D. et al. Alterations in brain transition metals in Huntington Disease: An evolving and intricate story. Arch. Neurol. 69, 887-893 (2012
113. van Oostrom, J. C. et al. Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington Disease. Neurology 65, 941-943 (2005
114. Majid, D. S. et al. Basal ganglia atrophy in prodromal Huntington's disease is detectable over one year using automated segmentation. Mov. Disord. 26, 2544-2551 (2011
115. Rizk-Jackson, A. et al. Evaluating imaging biomarkers for neurodegeneration in pre-symptomatic Huntington's disease using machine learning techniques. Neuroimage 56, 788-796 (2011
116. Scahill, R. I. et al. Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy. Hum. Brain Mapp. 34, 519-529 (2013
117. Jech, R. et al. Variation of selective gray and white matter atrophy in Huntington's disease. Mov. Disord. 22, 1783-1789 (2007
118. Jurgens, C. K. et al. Basal ganglia volume and clinical correlates in preclinical' Huntington's disease. J. Neurol. 255, 1785-1791 (2008
119. Squitieri, F. et al. Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington's disease. CNS Neurosci. Ther. 15, 1-11 (2009
120. Squitieri, F. et al. Atypical movement disorders in the early stages of Huntington's disease: Clinical and genetic analysis. Clin. Genet. 58, 50-56 (2000
121. Squitieri, F. et al. Highly disabling cerebellar presentation in Huntington Disease. Eur. J. Neurol. 10, 443-444 (2003
122. Wolf, R. C., Vasic, N., Schönfeldt-Lecuona, C., Landwehrmeyer, G. B. & Ecker, D. Dorsolateral prefrontal cortex dysfunction in presymptomatic Huntington's disease: Evidence from event-related fMRI. Brain 130, 2845-2857 (2007
123. Feigin, A. et al. Metabolic network abnormalities in early Huntington's disease: An [18F]FDG PET study. J. Nucl. Med. 42, 1591-1595 (2001
124. Shin, H. et al. Decreased metabolism in the cerebral cortex in early-stage Huntington's disease: A possible biomarker of disease progression?. J. Clin. Neurol. 9, 21-25 (2013
125. Feigin, A. et al. Thalamic metabolism and symptom onset in preclinical Huntington's disease. Brain 130, 2858-2867 (2007
126. Eidelberg, D. & Surmeier, D. J. Brain networks in Huntington Disease. J. Clin. Invest. 121, 484-492 (2011
127. Tang, C. C. et al. Metabolic network as a progression biomarker of premanifest Huntington's disease. J. Clin. Invest. 123, 4076-4088 (2013
128. Aylward, E. H. et al. Striatal volume contributes to the prediction of onset of Huntington Disease in incident cases. Biol. Psychiatry 71, 822-828 (2012
129. Ciarmiello, A. et al. 18F-FDG PET uptake in the pre-Huntington Disease caudate affects the time to onset independently of CAG expansion size. Eur. J. Nucl. Med. Mol. Imaging 39, 1030-1036 (2012
130. Wild, E. J. & Tabrizi, S. J. Biomarkers for Huntington's disease. Expert Opin. Med. Diagn. 2, 47-62 (2008
131. Scahill, R. I., Wild, E. J. & Tabrizi, S. J. Biomarkers for Huntington's disease: An update. Expert Opin. Med. Diagn. 6, 371-375 (2012
132. Hersch, S. M. et al. Creatine in Huntington Disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology 66, 250-252 (2006
133. Long, J. D., Matson, W. R., Juhl, A. R., Leavitt, B. R. & Paulsen, J. S. 8OHdG as a marker for Huntington Disease progression. Neurobiol. Dis. 46, 625-634 (2012
134. Borowsky, B. et al. 8OHdG is not a biomarker for Huntington Disease state or progression. Neurology 80, 1934-1941 (2013
135. Fang, Q. et al. Brain-specific proteins decline in the cerebrospinal fluid of humans with Huntington Disease. Mol. Cell. Proteomics 8, 451-466 (2009
136. Hu, Y. et al. Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington Disease activity in man and mouse. Proc. Natl Acad. Sci. USA 108, 17141-17146 (2011
137. Leoni, V. et al. Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease. Brain 131, 2851-2859 (2008
138. Weiss, A. et al. Single-step detection of mutant huntingtin in animal and human tissues: A bioassay for Huntington's disease. Anal. Biochem. 395, 8-15 (2009
139. Weiss, A. et al. Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression. J. Clin. Invest. 122, 3731-3736 (2012
140. Moscovitch-Lopatin, M. et al. Optimization of an HTRF assay for the detection of soluble mutant huntingtin in human buffy coats: A potential biomarker in blood for Huntington Disease. PLoS Curr. 2, RRN1205 (2010
141. Blennow, K., Hampel, H., Weiner, M. & Zetterberg, H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 6, 131-144 (2010
142. Rosas, H. D. et al. PRECREST: A phase II prevention and biomarker trial of creatine in at-risk Huntington Disease. Neurology http://dx.doi.org/10.1212/ WNL.0000000000000187
143. Jack, C. R. Jr et al. Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207-216 (2013
144. Langbehn, D. R., Brinkman, R. R., Falush, D., Paulsen, J. S. & Hayden, M. R. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin. Genet. 65, 267-277 (2004
145. Warner, J. H. & Hayden, M. A new model for age at onset in Huntington's Disease. Presented at CHDI Foundation Huntington's Disease Therapeutics Conference (Palm Springs, CA, USA, 2012
146. Langbehn, D. et al. Improving a simple Huntington Disease burden score. Presented at World Congress on Huntington's Disease (Melbourne, Australia, 2011.